Schrödinger, Inc. (SDGR)
Schrodinger (SDGR) Moves 14.1% Higher: Will This Strength Last?
Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Schrodinger price target raised to $28 from $27 at Goldman Sachs
Goldman Sachs raised the firm's price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company's Q3 results and announced deal with Novartis (NVS) involving both a research and expanded software utilization collaboration drove the stock higher, and while operating results from the quarter came in slightly below expectations, the management relayed confidence in the forward outlook for the balance of the year for the company's Software business, noting resiliency across large and mid-sized ACV accounts with increasing depth of utilization, the analyst tells investors in a research note. Schrodinger -0.165 (-0.74%) Novartis -1.08 (-1.03%)
Schrödinger (SDGR) Q3 2024 Earnings Call Transcript
Schrödinger Inc. (NASDAQ:SDGR ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Ramy Farid - President, Chief Executive Officer Karen Akinsanya - President, R&D and Therapeutics Geoff Porges - Chief Financial Officer Jaren Madden - Senior Vice President, Corporate Affairs and Investor Relations Conference Call Participants Matt - Jefferies Mani Foroohar - Leerink Partners Steve - Keybanc Gaspa - Morgan Stanley Evan Seigerman - BMO Capital Markets Joe Catanzaro - Piper Sandler Toff - Craig Hallum Brendan Smith - TD Cowen Sean Kim - Bank of America John - Citi Operator Welcome to Schrödinger's conference call to review our third quarter 2024 financial results. My name is Madison and I will be your Operator for today's call.
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.86 per share a year ago.
Schrödinger, Inc. (SDGR) Q2 2024 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Communications Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President R&D, Therapeutics Conference Call Participants Michael Yee - Jefferies Scott Schoenhaus - KeyBanc Conor McKay - BMO Capital Markets David Leibowitz - Citi Matt Hewitt - Craig-Hallam Capital Chris Shibutani - Goldman Sachs Steven Mah - TD Cowen Operator Thank you for standing by. Welcome to Schrödinger's Conference Call to review our Second Quarter 2024 Financial Results.
Compared to Estimates, Schrodinger (SDGR) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Schrodinger (SDGR) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.21 per share a year ago.
Earnings Preview: Schrodinger, Inc. (SDGR) Q2 Earnings Expected to Decline
Schrodinger (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Schrodinger: Buy The Drug-Discovery Platform And Get The Pipeline Nearly For Free
Schrödinger is a hybrid biopharma company specializing in physics-based computational chemistry and traditional drug development. The company aims to utilize computational methods to create better drug candidates and improve strategic decision-making in clinical trials. Schrödinger has attracted substantial investment from strategic partnerships and has a diverse pipeline of drug candidates in clinical development.
1 Growth Stock That Could Dominate AI's Next Breakthrough
Highlights from analysis from 24/7 Wall Street Analysts Eric Bleeker and Austin Smith can be found below.
